JP6883350B2 - Compositions for preventing or reducing hyperuricemia and methods for producing them - Google Patents
Compositions for preventing or reducing hyperuricemia and methods for producing them Download PDFInfo
- Publication number
- JP6883350B2 JP6883350B2 JP2019211858A JP2019211858A JP6883350B2 JP 6883350 B2 JP6883350 B2 JP 6883350B2 JP 2019211858 A JP2019211858 A JP 2019211858A JP 2019211858 A JP2019211858 A JP 2019211858A JP 6883350 B2 JP6883350 B2 JP 6883350B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mineral
- mineral component
- plant
- chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 44
- 201000001431 Hyperuricemia Diseases 0.000 title claims description 30
- 230000001603 reducing effect Effects 0.000 title claims description 21
- 238000000034 method Methods 0.000 title description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 95
- 239000011707 mineral Substances 0.000 claims description 95
- 241000196324 Embryophyta Species 0.000 claims description 75
- 229920001661 Chitosan Polymers 0.000 claims description 44
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 33
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 32
- 229940116269 uric acid Drugs 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 19
- 239000011261 inert gas Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000012298 atmosphere Substances 0.000 claims description 14
- 239000011777 magnesium Substances 0.000 claims description 13
- 230000006196 deacetylation Effects 0.000 claims description 11
- 238000003381 deacetylation reaction Methods 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- 229910052749 magnesium Inorganic materials 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 8
- 208000013824 Acidemia Diseases 0.000 claims description 7
- 208000010444 Acidosis Diseases 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 7
- 239000011591 potassium Substances 0.000 claims description 7
- 229910052700 potassium Inorganic materials 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 241001330002 Bambuseae Species 0.000 claims description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 4
- 241000018646 Pinus brutia Species 0.000 claims description 4
- 235000011613 Pinus brutia Nutrition 0.000 claims description 4
- 238000004380 ashing Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 244000065027 Artemisia princeps Species 0.000 claims description 3
- 235000017519 Artemisia princeps Nutrition 0.000 claims description 3
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 3
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 3
- 241001474374 Blennius Species 0.000 claims description 3
- 240000005109 Cryptomeria japonica Species 0.000 claims description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 3
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 3
- 240000001341 Reynoutria japonica Species 0.000 claims description 3
- 241000195474 Sargassum Species 0.000 claims description 3
- 244000111306 Torreya nucifera Species 0.000 claims description 3
- 235000006732 Torreya nucifera Nutrition 0.000 claims description 3
- 241001261506 Undaria pinnatifida Species 0.000 claims description 3
- 239000011425 bamboo Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 2
- 229910001410 inorganic ion Inorganic materials 0.000 claims description 2
- 235000010755 mineral Nutrition 0.000 description 83
- 210000002700 urine Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 24
- 150000003212 purines Chemical class 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 239000002956 ash Substances 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 235000013305 food Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 201000005569 Gout Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229960003975 potassium Drugs 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 239000001508 potassium citrate Substances 0.000 description 5
- 229960002635 potassium citrate Drugs 0.000 description 5
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 5
- 235000011082 potassium citrates Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000011362 coarse particle Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 208000037921 secondary disease Diseases 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 244000309146 drought grass Species 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- -1 having a β-1 Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000012858 packaging process Methods 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000254032 Acrididae Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 101100002917 Caenorhabditis elegans ash-2 gene Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- IDDRQDSRIZZVSG-UHFFFAOYSA-N azanium;2-iodylbenzoate Chemical compound [NH4+].[O-]C(=O)C1=CC=CC=C1I(=O)=O IDDRQDSRIZZVSG-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011738 major mineral Substances 0.000 description 1
- 235000011963 major mineral Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、高尿酸血症を予防又は軽減する組成物及びその製造方法に係り、より詳しくは、高尿酸血症の原因物質である尿酸の原料となるプリン体が食物から体内へ吸収されるのを阻止すると共に、生成した尿酸の尿への***量を増加させ、尿酸の血中濃度を低下させて高尿酸血症を予防又は症状を軽減させる組成物及びその製造方法に関する。 The present invention relates to a composition for preventing or reducing hyperuricemia and a method for producing the same. More specifically, purines, which are a raw material of uric acid, which is a causative substance of hyperuricemia, are absorbed from food into the body. The present invention relates to a composition for preventing or reducing hyperuricemia by increasing the amount of uric acid produced in urine and reducing the blood concentration of uric acid, and a method for producing the same.
高尿酸血症は、血液中の尿酸値が７．０ｍｇ／１００ｍＬ以上と定義され、二次疾患として痛風（関節炎）、腎障害、尿路結石、動脈硬化、高血圧、心臓病などの多様な病気を誘発する。ここで、痛風は、高尿酸血症患者の血液から析出した尿酸の針状の結晶が関節や腱の周りに沈着し組織を刺激して激痛を発生させる関節炎である。 Hyperuricemia is defined as a blood uric acid level of 7.0 mg / 100 mL or higher, and various secondary diseases such as gout (arthritis), nephropathy, urinary tract stones, arteriosclerosis, hypertension, and heart disease. Induce. Here, gout is an arthritis in which needle-shaped crystals of uric acid precipitated from the blood of a hyperuricemia patient are deposited around joints and tendons to stimulate tissues and cause severe pain.
尿酸は、ヒトにおいてはプリン体の最終代謝産物として生合成されて血液中に存在し、尿から***される。尿酸の原料となるプリン体は、生体内で核酸やエネルギーの代謝経路から生じる内因性プリン体、及び食物に含まれる核酸を消化することによって生成される外因性プリン体がある。 In humans, uric acid is biosynthesized as the final metabolite of purines, exists in blood, and is excreted from urine. Purines that are raw materials for uric acid include endogenous purines generated from the metabolic pathways of nucleic acids and energy in the living body, and exogenous purines produced by digesting nucleic acids contained in food.
従来は、食物由来のプリン体の摂取量は、体内で生産されるプリン体の生成量の２０％程度であったために、食物由来のプリン体の量は問題にならなかった。しかし、近年、日本人の食生活の変化に伴う肉類等の過剰摂取によって、飲食物から体内に取り込まれるプリン体の摂取量が著しく増大し、それに伴って高尿酸血症の患者が増加するという問題が発生した。
高尿酸血症は、更に通風をはじめとする多くの二次疾患を発症するために、生活習慣病の一つとして問題になってきた。しかも、高尿酸血症に対する治療方法は確立されておらず、高尿酸血症の発症及び二次疾患の予防と治療のための方法として、食事療法を継続的に実施することが推奨されているのが現状である。
Conventionally, since the intake of food-derived purines was about 20% of the amount of purines produced in the body, the amount of food-derived purines did not matter. However, in recent years, due to excessive intake of meat and the like due to changes in the dietary habits of Japanese people, the intake of purines taken into the body from food and drink has increased significantly, and the number of patients with hyperuricemia has increased accordingly. Problem has occurred.
Hyperuricemia has become a problem as one of the lifestyle-related diseases because it causes many secondary diseases such as gout. Moreover, no therapeutic method for hyperuricemia has been established, and continuous dietary therapy is recommended as a method for the prevention and treatment of the onset of hyperuricemia and secondary diseases. is the current situation.
高尿酸血症による尿酸量の低減方法に関しては、キトサンによる食物中のプリン体の吸収抑制作用が報告されている（特許文献１を参照）。この効果は、キトサンがプリン体と強い結合性を有し、プリン体の吸収を抑制することによるとされている。
キトサンの投与は、血液中の尿酸量の低減に一定の効果を上げるものの、外因性のプリン体の吸収を制限するだけのものであってその効果は制限的であり、高尿酸血症を根本的に治療するには不十分であった。
Regarding a method for reducing the amount of uric acid due to hyperuricemia, it has been reported that chitosan has an inhibitory effect on the absorption of purines in food (see Patent Document 1). It is said that this effect is due to the fact that chitosan has a strong binding property to purines and suppresses the absorption of purines.
Although administration of chitosan has a certain effect on reducing the amount of uric acid in the blood, it only limits the absorption of exogenous purines, and the effect is limited, which is fundamental to hyperuricemia. It was not enough to treat the disease.
一方、尿酸は、通常の代謝経路を介して血液中から尿へ排出されるため、尿酸の尿への排出量を増加させれば血液中の尿酸量は低下するものと考えられる。ここで、尿酸の尿に対する溶解度は、ｐＨ５．０では１５ｍｇ／１００ｍＬでありｐＨ７．０では２００ｍｇ／１００ｍＬであり、尿に対する尿酸の溶解度は、尿のｐＨの上昇に伴い飛躍的に上昇する。従って、尿のｐＨが上昇すれば、尿酸の血中から尿への排出量も増えると考えられる。 On the other hand, since uric acid is excreted from the blood to urine via a normal metabolic pathway, it is considered that if the amount of uric acid excreted into urine is increased, the amount of uric acid in the blood decreases. Here, the solubility of uric acid in urine is 15 mg / 100 mL at pH 5.0 and 200 mg / 100 mL at pH 7.0, and the solubility of uric acid in urine increases dramatically as the pH of urine increases. Therefore, it is considered that if the pH of urine rises, the amount of uric acid excreted from the blood into urine also increases.
また、健康なヒトの尿のｐＨは、時間によって変動し、１日尿のｐＨ（一日分を集めて測定した尿のｐＨ値）は通常６〜７．５の範囲である。しかし、一般的に高血圧症患者は、尿のｐＨが低く、特に、痛風（関節炎）を発症した患者の約４０％は、１日尿のｐＨが５．８以下であると言われている。また、尿***は人体に不必要なミネラルの排出経路であり、ヒトの尿のｐＨは、摂取したミネラルの影響を受けることが知られている。高尿酸血症の治療において、患者の尿のｐＨの管理は重要な事項である。 In addition, the pH of healthy human urine varies with time, and the pH of daily urine (pH value of urine measured by collecting daily doses) is usually in the range of 6 to 7.5. However, it is generally said that hypertensive patients have a low urine pH, and in particular, about 40% of patients who develop gout (arthritis) have a daily urine pH of 5.8 or less. In addition, urine excretion is an unnecessary mineral excretion route for the human body, and it is known that the pH of human urine is affected by the ingested minerals. Controlling the pH of a patient's urine is an important factor in the treatment of hyperuricemia.
尿のｐＨを上昇させて高尿酸血症を治療するために、種々の尿のｐＨ上昇剤が使用されているが（例えば特許文献２を参照）、いずれも作用が緩和であって高尿酸血症の患者に対して効果を上げるのに長期間を有するのが実情である。また、高尿酸血症の患者は基礎的な健康状態が悪化し、他の合併症を併発したり、治療薬の副作用が惹起されたりする場合もあり、高尿酸血症患者の尿のｐＨの管理は容易なことではなかった。 Various urinary pH-increasing agents have been used to increase the pH of urine to treat hyperuricemia (see, for example, Patent Document 2), but all have mild effects and hyperuricemia. The reality is that it takes a long time to be effective for patients with illness. In addition, patients with hyperuricemia may have worsening basic health conditions, may have other complications, and may have side effects of therapeutic agents. It was not easy to manage.
ここで、ヒトの体に含まれるミネラルは、主要ミネラルとしてはカルシウム、リン、イオウ、カリウム、ナトリウム、マグネシウム、塩素の７種類であり、また微量ミネラルとしては鉄、ヨウ素、亜鉛、銅、セレン、マンガン、コバルト、モリブデン、クロムが挙げられ、更に毒性量以下の鉛、水銀、カドミウム等も含まれる。 Here, the minerals contained in the human body are seven types of major minerals, calcium, phosphorus, sulfur, potassium, sodium, magnesium, and chlorine, and trace minerals are iron, iodine, zinc, copper, selenium, and so on. Examples include manganese, cobalt, molybdenum and chromium, and also include lead, mercury, calcium and the like having a toxic amount or less.
ミネラルを摂取する場合は、食物から摂取するのが通常である。しかし、食物に含まれるミネラルは必要量に対して不足する場合もある。ミネラルの不足によるヒトの健康障害の治療や予防には、人工的に製造されたミネラルを補給することが多い。しかし、この方法では、体内への吸収が悪く、大半のミネラルが吸収されずに糞尿と共に***され、あるいは過剰摂取の問題、又は異物として拒否反応をもたらす等の不都合がある。 When ingesting minerals, it is usually taken from food. However, the minerals contained in food may be insufficient for the required amount. Artificially produced minerals are often supplemented to treat or prevent human health problems due to mineral deficiency. However, this method has disadvantages such as poor absorption into the body, excretion of most minerals together with manure without being absorbed, a problem of overdose, or a rejection reaction as a foreign substance.
一方、ミネラルは食物と共に人体に吸収されるのが最も自然であるが、これらの食物には必ずしも必要量のミネラルが含有されているとは限らず、更に多くの食物が、人体にとっての有害な有機物を含んでいる場合があるため、十分なミネラルを人の食生活のみから安全に摂取することは困難である。 Minerals, on the other hand, are most naturally absorbed by the human body along with food, but these foods do not always contain the required amount of minerals, and more foods are harmful to the human body. Since it may contain organic substances, it is difficult to safely ingest sufficient minerals only from the human diet.
このような問題を解消するために、特許文献３には、植物を加熱し溶融したものから抽出した、安全で人体への吸収率が高く、ミネラル量の相互のバランスが取れ、酸化還元電位が−２００ｍＶ以下の還元性を有する生物ミネラルの製造方法が開示されている。しかし、特許文献３に記載された生物ミネラルは、酸化還元電位の強さがまだ不足し、尿のｐＨ上昇作用は記載されていない。 In order to solve such a problem, Patent Document 3 states that a plant is extracted from a heated and melted plant, which is safe and has a high absorption rate into the human body, has a mutual balance of mineral amounts, and has an oxidation-reduction potential. A method for producing a biomineral having a reducing property of −200 mV or less is disclosed. However, the biological mineral described in Patent Document 3 still lacks the strength of the redox potential, and the action of raising the pH of urine is not described.
本発明は、高尿酸血症の原因物質である尿酸の原料となるプリン体の食物から体内への吸収を制限すると共に、プリン体から生成された尿酸及び体内で生成された尿酸の尿中への排出を促進させ、血中の尿酸濃度を低下させることによって高尿酸血症を予防又は軽減する、植物ミネラルとキトサンとを含む組成物を提供することを課題とする。 The present invention limits the absorption of purines, which are the raw material of uric acid, which is a causative agent of hyperuricemia, from food into the body, and also into the urine of uric acid produced from purines and uric acid produced in the body. It is an object of the present invention to provide a composition containing a plant mineral and chitosan, which promotes the excretion of hyperuricemia and prevents or reduces hyperuricemia by lowering the concentration of uric acid in the blood.
また本発明は、高尿酸血症の患者に投与可能な、植物ミネラルとキトサンとを含む組成物の製造方法を提供することを課題とする。 Another object of the present invention is to provide a method for producing a composition containing a plant mineral and chitosan, which can be administered to a patient with hyperuricemia.
本発明は、かかる課題を解決するためになされたものであって、本発明の高尿酸血症を予防又は軽減する組成物は、脱アセチル化度が８０％以上であるキトサンと、原料植物の灰分から得た植物由来のミネラル成分と、を含み、植物由来のミネラル成分が、質量％で、ナトリウム（Ｎａ）０．４〜１．６％、カリウム（Ｋ）０．７〜２．８％、カルシウム（Ｃａ）５．７〜２３．０％、及びマグネシウム（Ｍｇ）１．４〜５．６％を含むことを特徴とする。
The present invention has been made to solve such a problem, and the composition for preventing or reducing hyperuric acidemia of the present invention comprises chitosan having a deacetylation degree of 80% or more, and a raw material plant. look-containing mineral components derived from plants obtained from ash, the mineral components derived from plants, in mass%, sodium (Na) 0.4-1.6%, potassium (K) .7-2.8 %, calcium (Ca) 5.7 to 23.0%, and 1.4 to 5.6% magnesium (Mg), characterized in including Mukoto.
前記植物由来のミネラル成分は、原料植物がヒバマタ、ホンダワラ、アラメ、ワカメ、コンブ、竹、スギ、ヒノキ、松、ヨモギ、イタドリ若芽、熊笹、又はカヤから選ばれる１以上を含むことが好ましい。
The plant-derived mineral component preferably contains one or more of the raw material plants selected from hibamata, sargassum, arame, wakame seaweed, kelp, bamboo, sugi, hinoki, pine, yomogi, itadori young shoots, bear bamboo grass, and kaya.
前記植物由来のミネラル成分は、質量％で、ナトリウム（Ｎａ）０．４〜１．６％、カリウム（Ｋ）０．７〜２．８％、カルシウム５．７〜２３．０％、及びマグネシウム（Ｍｇ）１．４〜５．６％を含むことができる。 The plant-derived mineral components are sodium (Na) 0.4 to 1.6%, potassium (K) 0.7 to 2.8%, calcium 5.7 to 23.0%, and magnesium in mass%. (Mg) can contain 1.4 to 5.6%.
前記ミネラル成分抽出液の酸化還元電位が−６００ｍＶ以下であることが好ましい。
前記キトサンと前記植物由来のミネラル成分との質量比が１：１〜６：１であることが好ましい。
The redox potential of the mineral component extract is preferably −600 mV or less.
The mass ratio of the chitosan to the plant-derived mineral component is preferably 1: 1 to 6: 1.
また本発明の高尿酸血症を予防又は軽減する組成物の製造方法は、請求項１乃至３のいずれか１項に記載の高尿酸血症を予防又は軽減する組成物の製造方法であって、脱アセチル化度が８０％以上であるキトサンと、原料植物の灰分から得た植物由来のミネラル成分と、を含み、ミネラル成分は、原料植物を不活性雰囲気中で６５０℃以上に加熱することによって灰化し、得られた灰分を粉砕し、粉砕された灰分から可溶なミネラル成分を水で抽出し、生成したミネラル成分抽出液の水分を蒸発させ粉末化して製造することを特徴とする。
The method for producing a composition for preventing or reducing hyperuric acidemia of the present invention is the method for producing a composition for preventing or reducing hyperuric acidemia according to any one of claims 1 to 3. It contains chitosan having a deacetylation degree of 80% or more and a plant-derived mineral component obtained from the ash content of the raw material plant, and the mineral component is to heat the raw material plant to 650 ° C. or higher in an inert atmosphere. The ash content obtained is crushed, a soluble mineral component is extracted from the crushed ash content with water, and the water content of the produced mineral component extract is evaporated and powdered to produce the product.
前記ミネラル成分抽出液は、灰分を２００メッシュ以下に粉砕し、可溶なミネラル成分を、無機イオンを除去した水で抽出して製造することが好ましい。
前記ミネラル成分抽出液の製造工程は、酸化還元電位が−６００ｍＶ以下になるように不活性ガスが注入されることができる。
前記ミネラル成分抽出液の製造工程は、前記ミネラル成分抽出液の酸化還元電位が−６００ｍＶ未満の場合は、酸化還元電位が−６００ｍＶ以下になるように不活性ガスが注入されることができる。
The mineral component extract is preferably produced by pulverizing the ash content to 200 mesh or less and extracting the soluble mineral component with water from which inorganic ions have been removed.
In the manufacturing process of the mineral component extract, an inert gas can be injected so that the redox potential becomes −600 mV or less.
In the manufacturing process of the mineral component extract, when the redox potential of the mineral component extract is less than −600 mV, an inert gas can be injected so that the redox potential becomes −600 mV or less.
食物からのプリン体の吸収を抑制するキトサンと、植物を不活性気体の雰囲気中で灰化して生成した灰分から抽出して得た植物由来のミネラル成分と、を含む組成物を投与することによって、高尿酸血症を予防又は軽減することができる。
また、本発明の植物由来のミネラル成分は、−６００ｍＶ以下という強い還元力を有し、有害な過酸化ラジカルを還元して高尿酸血症の患者の健康状態を改善することができる。
By administering a composition containing chitosan, which suppresses the absorption of purines from food, and a plant-derived mineral component obtained by extracting the ash produced by ashing the plant in an atmosphere of an inert gas. , Hyperuricemia can be prevented or alleviated.
In addition, the plant-derived mineral component of the present invention has a strong reducing power of −600 mV or less, and can reduce harmful peroxide radicals to improve the health condition of patients with hyperuricemia.
以下に、添付した図面を参照して、本発明の実施の形態を詳細に記載する。この記載は、本発明を説明するためのものであって、この記載によって本発明の技術範囲を限定するものではない。本発明は、本発明の技術的範囲から逸脱しない範囲内で多様に変更して実施することが可能である。 Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings. This description is for the purpose of explaining the present invention, and does not limit the technical scope of the present invention by this description. The present invention can be variously modified and implemented without departing from the technical scope of the present invention.
本発明者は、尿酸の前駆体であるプリン体が体内に吸収されるのを抑制するキトサンと、尿酸の尿への***を増加させる植物由来のミネラルと、を含む組成物を投与することにより、高尿酸血症患者の血液中の尿酸濃度を低下させ、高尿酸血症を防止し痛風へ進行するのを阻止することができると共に痛風の症状を軽減できることを見出して本発明を完成させた。 The present inventor administers a composition containing chitosan, which suppresses the absorption of purines, which are precursors of uric acid, into the body, and plant-derived minerals, which increase the excretion of uric acid into urine. The present invention has been completed by finding that it is possible to reduce the uric acid concentration in the blood of a hyperuricemia patient, prevent hyperuricemia and prevent the progression to gout, and reduce the symptoms of gout. ..
図１は、本発明の組成物の製造工程を示すブロック図である。
図１に示すように、本発明の高尿酸血症を予防又は軽減する組成物２０は、脱アセチル化度が８０％以上であるキトサン（６）と、植物１を不活性気体の雰囲気中で灰化し生成した灰化物２を粉砕工程で粉砕して得た灰化物粉末（３）から抽出して得た植物ミネラル（１０）とを含んでなる。
FIG. 1 is a block diagram showing a manufacturing process of the composition of the present invention.
As shown in FIG. 1, the composition 20 for preventing or reducing hyperuric acidemia of the present invention comprises chitosan (6) having a deacetylation degree of 80% or more and plant 1 in an atmosphere of an inert gas. It contains a plant mineral (10) obtained by extracting from the ash powder (3) obtained by crushing the ashed product 2 produced by ashing in a crushing step.
［キトサン］
キトサンとは、キチン（β−１，４−ポリ−Ｎ−アセチルグルコサミン）の脱アセチル化物であり、β−１，４−ポリグルコサミン構造を主とする多糖類である。キトサンは、カニ、エビ、オキアミなどの甲殻類の甲皮や、カブトムシ、バッタなどの昆虫類の甲皮などを脱カルシウム処理し、除蛋白処理をして得られるキチンを、例えば、苛性ソーダで脱アセチル化することによって得ることができる。
[Chitosan]
Chitosan is a deacetylase of chitin (β-1,4-poly-N-acetylglucosamine), and is a polysaccharide mainly having a β-1,4-polyglucosamine structure. Chitosan decalcifies the crustacean shells of crabs, shrimp, krill, etc., and the shells of insects such as beetles, grasshoppers, etc. It can be obtained by acetylation.
通常は、キチンからの脱アセチル化度が約６０％以上のものをキトサンというが、本発明では、脱アセチル化率が８０％以上であることが好ましい。また、脱アセチル化度が９０％以上であるキトサンがより好ましく、最も好ましい事例として脱アセチル化度が９５％以上であるキトサンを挙げることができる。このようなキトサンは市販品が購入可能である。キトサンの脱アセチル化率が８０％未満であると、消化管内におけるプリン体との結合率が低下することがあり、好ましくない。 Usually, chitosan has a degree of deacetylation from chitin of about 60% or more, but in the present invention, the degree of deacetylation is preferably 80% or more. Further, chitosan having a deacetylation degree of 90% or more is more preferable, and as the most preferable example, chitosan having a deacetylation degree of 95% or more can be mentioned. Commercially available products of such chitosan are available. If the deacetylation rate of chitosan is less than 80%, the binding rate with purines in the digestive tract may decrease, which is not preferable.
［植物由来のミネラル］
本発明は、植物１を不活性気体の雰囲気で灰化し生成した灰化物２から抽出して得た植物由来のミネラル（以下、「植物ミネラル」と記す）を更に含む。
本発明の植物ミネラル１０は、植物１を不活性雰囲気中で６５０℃以上に加熱することによって灰化し、得られた灰化物２を粉砕し、灰化物粉末３から可溶なミネラル成分を水で抽出し、ミネラル成分抽出液５の水分を蒸発させて製造することができる。
[Plant-derived minerals]
The present invention further includes plant-derived minerals (hereinafter referred to as "plant minerals") obtained by extracting plant 1 from ashes 2 produced by incineration in an atmosphere of an inert gas.
The plant mineral 10 of the present invention is incinerated by heating plant 1 to 650 ° C. or higher in an inert atmosphere, the obtained ashes 2 are crushed, and soluble mineral components are extracted from the ashes powder 3 with water. It can be produced by extracting and evaporating the water content of the mineral component extract 5.
植物１を不活性雰囲気中で加熱、灰化すると、有機物が酸化分解される際に酸素と反応するので、残留する灰化物２は酸素欠乏になり還元性を有することになる。灰化物２に水を加えて製造した本発明の植物ミネラル成分のミネラル成分抽出液５は、酸化還元電位が−６００ｍＶ以下であることが好ましい。酸化還元電位が−６００ｍＶ未満の場合は、酸化還元電位が−６００ｍＶ以下になるように不活性ガスの注入量を増加することが好ましい。
本発明の植物ミネラル１０は、無機試薬を加え合わせて製造した通常の無機塩混合物とは異なるものであり、生体に吸収されやすいという特徴を有する。
When the plant 1 is heated and ashed in an inert atmosphere, the organic matter reacts with oxygen when it is oxidatively decomposed, so that the residual ash 2 becomes oxygen deficient and has reducing property. The mineral component extract 5 of the plant mineral component of the present invention produced by adding water to the ash product 2 preferably has an oxidation-reduction potential of −600 mV or less. When the redox potential is less than −600 mV, it is preferable to increase the injection amount of the inert gas so that the redox potential becomes −600 mV or less.
The plant mineral 10 of the present invention is different from a normal inorganic salt mixture produced by adding an inorganic reagent, and has a characteristic that it is easily absorbed by a living body.
また本発明の植物ミネラル１０は、質量％で、ミネラル成分を１００質量％とした場合にナトリウム（Ｎａ）０．４〜１．６％、カリウム（Ｋ）０．７〜２．８％、カルシウム５．７〜２３．０％、及びマグネシウム（Ｍｇ）１．４〜５．６％を含むことが好ましい。この植物ミネラル１０の成分の中では、特にカリウム及びマグネシウムがナトリウムより高い比率で含まれることが注目される。 Further, the plant mineral 10 of the present invention is based on mass%, and when the mineral component is 100% by mass, sodium (Na) 0.4 to 1.6%, potassium (K) 0.7 to 2.8%, and calcium. It preferably contains 5.7 to 23.0% and 1.4 to 5.6% magnesium (Mg). It is noted that among the components of the plant mineral 10, potassium and magnesium are particularly contained in a higher ratio than sodium.
マグネシウムは植物１の葉緑素の中心金属として酸素原子とは結合せずに存在して光合成にかかわる。植物１を不活性雰囲気中で加熱すると、マグネシウム塩の分解点が低いために（炭酸マグネシウムは、３５０℃で分解して酸化マグネシウムになる）周囲から酸素原子を奪うために灰化物２は強い還元性を有し、マグネシウムはアルカリ性の酸化マグネシウムとして存在することになる。また、マグネシウムは種々の生理作用にかかわる補酵素でもある。
また、植物ミネラル１０は、還元性を有するので、有害な過酸化ラジカルを消去でき、摂取者の健康を増進することができるという特徴を有する。
Magnesium exists as the central metal of chlorophyll in Plant 1 without being bound to oxygen atoms and is involved in photosynthesis. When plant 1 is heated in an inert atmosphere, the decomposition point of magnesium salt is low (magnesium carbonate decomposes at 350 ° C to magnesium oxide), so the ashide 2 is strongly reduced to deprive the surroundings of oxygen atoms. Having the property, magnesium will exist as alkaline magnesium oxide. Magnesium is also a coenzyme involved in various physiological actions.
Further, since the plant mineral 10 has a reducing property, it has a feature that harmful radical peroxides can be eliminated and the health of the ingestor can be improved.
キトサン６と植物ミネラル１０とは、質量比が１：１〜６：１であることが好ましい。キトサン６に対する植物ミネラル１０の質量比が６：１以下では、植物ミネラル１０の効果が出ないことがあり、１：１以上加えても、加えた量に比較して植物ミネラルの効果は増大せず、かえって塩分の取りすぎになる可能性があるので好ましくない。 The mass ratio of chitosan 6 and plant mineral 10 is preferably 1: 1 to 6: 1. If the mass ratio of plant mineral 10 to chitosan 6 is 6: 1 or less, the effect of plant mineral 10 may not be obtained, and even if 1: 1 or more is added, the effect of plant mineral is increased compared to the added amount. On the contrary, it is not preferable because it may take too much salt.
本発明の１実施形態として、血中尿酸濃度が７．４ｍｇ／１００ｍＬである高尿酸血症の患者であって、通風を発症して両手指の掌に近い部分が発赤し腫れあがって疼痛を訴える患者に、キトサンと植物ミネラルとの質量比が３：１である組成物４．０ｇを、１日３回ずつ３週間連続投与したところ、血中尿酸濃度が７．０ｍｇ／１００ｍＬ以下に低下し、関節部の発赤及び腫れが治り、疼痛もおさまるという効果があった。 As one embodiment of the present invention, in a patient with hyperuricemia having a blood uric acid concentration of 7.4 mg / 100 mL, gout develops and the portion near the palms of both hands becomes red and swollen and causes pain. When 4.0 g of a composition having a mass ratio of chitosan to plant minerals of 3: 1 was continuously administered to the complaining patient three times a day for 3 weeks, the blood uric acid concentration decreased to 7.0 mg / 100 mL or less. However, it had the effect of healing the redness and swelling of the joints and reducing the pain.
以下に、植物ミネラルの製造方法を記載する。
１．植物ミネラルの製造
（１）灰化工程
原料の植物１を、不活性気体の雰囲気下、加熱炉で６５０℃〜１０００℃の温度範囲で加熱して、植物１の有機物を分解して灰化物２を得る。６５０℃以上に加熱することによって農薬、殺虫剤、及び添加剤等の有機性有害物質は分解除去される。不活性気体としては、例えば窒素ガスやアルゴンガスなどを用いることができるが、不活性気体はこれらに限られるものではない。また、原料の植物としては、例えば、ヒバマタ、ホンダワラ、アラメ、ワカメ、コンブ、竹、スギ、ヒノキ、松、ヨモギ、イタドリ若芽、熊笹、又はカヤから選ばれる１以上をあげることが出来るが、原料植物はこれらに限られるものではない。
The method for producing plant minerals is described below.
1. 1. Production of plant minerals (1) Incineration process The raw material plant 1 is heated in a heating furnace in a temperature range of 650 ° C to 1000 ° C in an atmosphere of an inert gas to decompose the organic matter of the plant 1 and ash it 2. To get. By heating to 650 ° C. or higher, organic harmful substances such as pesticides, pesticides and additives are decomposed and removed. As the inert gas, for example, nitrogen gas or argon gas can be used, but the inert gas is not limited to these. In addition, as the raw material plant, for example, one or more selected from hibamata, sargassum, arame, wakame seaweed, kelp, bamboo, sugi, hinoki, pine, yomogi, Japanese knotweed young shoot, bear bamboo grass, or kaya can be mentioned, but the raw material. Plants are not limited to these.
（２）粉砕工程
灰化工程で得た灰化物２を、不活性気体の雰囲気下で（ＪＩＳ）１００〜５００メッシュ篩通過画分が得られるように粉砕機で粉砕して灰化物粉末３を得る。
（３）植物ミネラル抽出工程
灰化物粉末３に不活性気体の雰囲気下で水を加え混合し、可溶なミネラル分を溶解させる。水としては、鉱物性ミネラルを含まないＲＯ膜（逆浸透膜）処理水、又はイオン交換水を蒸留して得た蒸留水などを脱気したものが好適である。得られた混合液を、不活性気体の雰囲気下で加圧しながら２００メッシュの篩で濾過してミネラル成分抽出液５と粗粒子成分４とに分離し、ミネラル成分抽出液５を得る。粗粒子成分４は、粉砕段階へ戻され、再粉砕される。
(2) Crushing step The ashed product 2 obtained in the ashing step is crushed with a crusher in an atmosphere of an inert gas so as to obtain a (JIS) 100-500 mesh sieve passing fraction to obtain an ashed powder 3. obtain.
(3) Plant mineral extraction step Water is added to the ash powder 3 in an atmosphere of an inert gas and mixed to dissolve the soluble minerals. As the water, RO membrane (reverse osmosis membrane) treated water containing no mineral minerals, distilled water obtained by distilling ion-exchanged water, or the like is preferably degassed. The obtained mixed liquid is filtered through a 200-mesh sieve while pressurizing under an atmosphere of an inert gas to separate the mineral component extract 5 and the coarse particle component 4, to obtain the mineral component extract 5. The coarse particle component 4 is returned to the pulverization stage and re-pulverized.
（５）乾燥工程
ミネラル成分抽出液５を、不活性気体の雰囲気下で凍結乾燥機またはスプレ−ドライヤー等を用いて乾燥、粉末化して植物ミネラル１０の粉末を得る。
（６）製剤、包装工程
製剤、包装工程は、公知の方法で行うことができる。例えば、乾燥工程で得た植物ミネラル１０の粉末とのキトサン６の粉末とを質量比で不活性気体の雰囲気下で１：１〜１：６の範囲で混合し、酸素透過率の低いフィルム等からなる袋体に不活性ガスと共に封入するか真空包装して、本発明に係る組成物を製造することができる。また、キトサン６は、例えば乳酸塩などの水溶液に溶解してミネラル成分抽出液５と混合し、乾燥、粉末化して植物ミネラル１０の粉末を得ることもできる。
(5) Drying Step The mineral component extract 5 is dried and pulverized in an atmosphere of an inert gas using a freeze dryer, a spray dryer, or the like to obtain a powder of plant mineral 10.
(6) Formulation and packaging process The formulation and packaging process can be carried out by a known method. For example, a film obtained by mixing the powder of plant mineral 10 obtained in the drying step and the powder of chitosan 6 in a mass ratio in the range of 1: 1 to 1: 6 in an atmosphere of an inert gas to have a low oxygen permeability, or the like. The composition according to the present invention can be produced by encapsulating or vacuum-packing the bag body made of the above with an inert gas. Further, chitosan 6 can be dissolved in an aqueous solution such as lactate, mixed with the mineral component extract 5, dried and powdered to obtain a powder of plant mineral 10.
上記の方法によって生のままの松葉、よもぎ等を灰化した場合には、１，０００ｋｇの原料で約２０〜１００ｋｇ相当の植物ミネラル１０（質量で原料１／５０〜１／１０）の抽出が可能である。 When raw pine needles, mugwort, etc. are incinerated by the above method, 1,000 kg of raw material can extract about 20 to 100 kg of plant mineral 10 (1/50 to 1/10 of the raw material by mass). It is possible.
「製造例」植物ミネラル
上記の方法を用いて植物１０００ｋｇを上記（１）〜（５）の方法をにより、不活性気体として窒素ガスを用い、電気炉中７００℃で灰化し、ＲＯ水を用いて抽出し、ろ過し、ろ液をスプレードライヤーを用いて乾燥して５３．１ｋｇの植物ミネラル１０を得た。
得られた植物ミネラル１０の成分を表１に示す。
"Production example" Plant minerals 1000 kg of plants are incinerated by the above methods (1) to (5) using nitrogen gas as an inert gas at 700 ° C. in an electric furnace, and RO water is used. The mixture was extracted, filtered, and the filtrate was dried using a spray dryer to obtain 53.1 kg of plant mineral 10.
The components of the obtained plant mineral 10 are shown in Table 1.
植物ミネラル１００ｇ中の成分
［実施例１］植物ミネラルとキトサンとの組成物
５３ｋｇの植物ミネラル１０を含むミネラル成分抽出液５に、脱アセチル化率８０％のキトサン１６０ｋｇと、乳酸８９ｋｇとを窒素雰囲気下で溶解し、スプレードライヤーで乾燥させて２８７ｋｇの植物ミネラルとキトサン（乳酸塩）との組成物２０を得た。実施例のキトサンと植物ミネラルとの質量比は３：１である。
[Example 1] Composition of plant mineral and chitosan 160 kg of chitosan having an deacetylation rate of 80% and 89 kg of lactic acid are dissolved in a mineral component extract 5 containing 53 kg of plant mineral 10 in a nitrogen atmosphere and sprayed. Drying with a dryer gave 287 kg of a composition 20 of plant minerals and chitosan (lactate). The mass ratio of chitosan to plant minerals in the examples is 3: 1.
［比較例１］
実施例１と同様に、但しキトサン６の乳酸塩を含み植物ミネラル１０を含まない組成物を製造した。
[Comparative Example 1]
Similar to Example 1, however, a composition containing the lactate of chitosan 6 and not containing the plant mineral 10 was produced.
［比較例２］
実施例１と同様に、但し植物ミネラル１０を含みキトサン６の乳酸塩を含まない組成物を製造した。
[Comparative Example 2]
Similar to Example 1, however, a composition containing plant mineral 10 and no lactate of chitosan 6 was produced.
［比較例３］
実施例１と同様に、但しキトサン６の乳酸塩を含み、植物ミネラル１０の代わりにクエン酸ナトリウムとクエン酸カリウムの質量比１：１の混合物５０ｋｇを含む組成物を製造した。比較例３のキトサンとクエン酸ナトリウムとクエン酸カリウムの質量比１：１の混合物との質量比は１：１である。
[Comparative Example 3]
Similar to Example 1, however, a composition containing the lactate of chitosan 6 and containing 50 kg of a 1: 1 mass ratio mixture of sodium citrate and potassium citrate instead of the plant mineral 10 was produced. The mass ratio of chitosan, sodium citrate, and potassium citrate in Comparative Example 3 to a mixture having a mass ratio of 1: 1 is 1: 1.
［実施例２］
５週齢の雄性Ｗｉｓｔａｒラットを３日間馴化飼育し、実験に使用した。馴化および実験期間中を通じて、動物飼育室の飼育条件は、室温２３±２℃、湿度５５±１５％、換気回数は１５回／時間、照明時間は１日あたり１２時間とした。飲料水は、自由に摂取させた。
[Example 2]
Five-week-old male Wistar rats were acclimated and bred for 3 days and used in the experiment. Throughout the acclimatization and experimental period, the animal breeding room was bred at room temperature of 23 ± 2 ° C., humidity of 55 ± 15%, ventilation rate of 15 times / hour, and lighting time of 12 hours per day. Drinking water was allowed to be ingested freely.
３日間の馴化後、ラットを５群に分け（１群あたり１０匹）、ＲＮＡ３重量％と各被験薬３重量％を含有させた餌を４日間にわたって１日あたり１５ｇ／ｋｇ与えた。詳細には、第１群のラットには被験薬として実施例の組成物２０を与え、第２群のラットには被験薬として比較例１の組成物を与え、第３群のラットには被験薬として比較例２の組成物を与え、第４群のラットには被験薬として比較例３の組成物を与えた。対照例のラットに対しては、被験薬を含まない以外は第１〜４群と同様の餌（同量のＲＮＡのみを含有させた餌）を与えた。
なお、測定値は各群の算術平均値である。
After acclimation for 3 days, the rats were divided into 5 groups (10 per group) and fed a diet containing 3% by weight of RNA and 3% by weight of each test drug at 15 g / kg per day for 4 days. Specifically, the rats in the first group were given the composition of Example 20 as the test drug, the rats in the second group were given the composition of Comparative Example 1 as the test drug, and the rats in the third group were tested. The composition of Comparative Example 2 was given as a drug, and the rat of Group 4 was given the composition of Comparative Example 3 as a test drug. The rats of the control example were fed the same diet as in groups 1 to 4 (a diet containing only the same amount of RNA) except that the test drug was not contained.
The measured value is the arithmetic mean value of each group.
各群の尿を１か所に集め、各群の２４時間尿ｐＨを測定し表２に示した。
試験期間の最終日に、尿酸代謝酵素の阻害剤であるオキソ酸カリウムを２５０ｍｇ／ｋｇとなるよう腹腔内注射して、その２時間後に採血した。採血した血液を１時間室温で放置した後、３０００×ｇで１０分間遠心分離を行うことで血漿を得た。血漿中の尿酸値は、市販のキット（尿酸Ｃ テストワコー、和光純薬工業株式会社製）により測定した。キットは、その使用説明書に従って使用した。
この結果を表３に示す（血中尿酸量の単位はｍｇ／１００ｍＬ血液）。
On the final day of the test period, potassium oxoate, an inhibitor of uric acid-metabolizing enzyme, was injected intraperitoneally to 250 mg / kg, and blood was collected 2 hours later. Plasma was obtained by allowing the collected blood to stand at room temperature for 1 hour and then centrifuging at 3000 × g for 10 minutes. The uric acid level in plasma was measured with a commercially available kit (Uric Acid C Test Wako, manufactured by Wako Pure Chemical Industries, Ltd.). The kit was used according to its instructions for use.
The results are shown in Table 3 (the unit of blood uric acid amount is mg / 100 mL blood).
試験第１日目には、各群のラットはＲＮＡの過剰摂取によって高尿酸血症を発症して２４時間尿のｐＨ値が低下した。
On the first day of the study, rats in each group developed hyperuricemia due to RNA overdose and the pH value of urine decreased for 24 hours.
比較例１のキトサンのみを与えたラット及び比較例３のクエン酸ナトリウムとクエン酸カリウムの質量比１：１の混合物及びキトサンを投与したラットの尿のｐＨ値は、試験薬を何も与えないラットの尿のｐＨ値とほぼ同等であった。クエン酸ナトリウムとクエン酸カリウムの混合物は、本実験系では効果を示さなかった。比較例２及び本発明のキトサンと植物ミネラルとの組成物を投与したラットの尿のｐＨ値は、２日目から著しい改善を示した。
なお、キトサンに対する植物ミネラルの質量比が６：１未満の組成物は、尿のｐＨ値の有意な改善効果を示さないことがあり、好ましくない。
The pH values of the urine of rats fed only Chitosan of Comparative Example 1 and a mixture of sodium citrate and potassium citrate in a mass ratio of 1: 1 and rats treated with chitosan gave no test drug. It was almost the same as the pH value of rat urine. A mixture of sodium citrate and potassium citrate had no effect in this experimental system. The pH value of the urine of the rat to which the composition of Comparative Example 2 and the chitosan of the present invention and the plant mineral was administered showed a remarkable improvement from the second day.
A composition in which the mass ratio of plant minerals to chitosan is less than 6: 1 may not show a significant improving effect on the pH value of urine, which is not preferable.
表３に示すように、試験終了時［４日後］の対象例の尿酸の血中濃度は７．５ｍｇ／１００ｍＬ血液であり、高尿酸血症を発症していた。
比較例１のキトサンのみを与えたラット及び比較例２の植物ミネラルのみを与えたラットの血中尿酸濃度は、それぞれ６．３及び５．７ｍｇ／１００ｍＬ血液であり、やや改善を示したものの、不十分であった。また、比較例３のキトサンと、クエン酸ナトリウムとクエン酸カリウムの質量比１：１の混合物と、を投与したラットの血中尿酸濃度は６．２ｍｇ／１００ｍＬ血液であり、比較例１のキトサンのみを与えたラットと同様であった。
一方、実施例に示すように、本発明のキトサンと植物ミネラルを含む組成物を投与したラットの血中尿酸濃度は３．２ｍｇ／１００ｍＬ血液であり、大幅な改善を示した。
As shown in Table 3, the blood concentration of uric acid in the target example at the end of the test [4 days later] was 7.5 mg / 100 mL blood, and hyperuricemia had developed.
The blood uric acid concentrations of the rats fed only chitosan of Comparative Example 1 and the rats fed only the plant minerals of Comparative Example 2 were 6.3 and 5.7 mg / 100 mL blood, respectively, and although they showed a slight improvement, they showed a slight improvement. It was inadequate. Further, the blood uric acid concentration of the rat to which the chitosan of Comparative Example 3 and the mixture of sodium citrate and potassium citrate in a mass ratio of 1: 1 was administered was 6.2 mg / 100 mL blood, and the chitosan of Comparative Example 1 was obtained. It was similar to the rats fed only.
On the other hand, as shown in Examples, the blood uric acid concentration of rats to which the composition containing chitosan and plant minerals of the present invention was administered was 3.2 mg / 100 mL blood, showing a significant improvement.
以上、本発明に関する好ましい実施形態を説明したが、本発明は前記実施形態に限定されず、本発明の属する技術範囲を逸脱しない範囲での全ての変更が含まれる。 Although the preferred embodiment of the present invention has been described above, the present invention is not limited to the above-described embodiment, and includes all modifications within a range not departing from the technical scope to which the present invention belongs.
１ 原料植物
２ 灰化物
３ 灰化物粉末
４ 粗粒子成分
５ ミネラル成分抽出液
６ キトサン
１０ 植物ミネラル
２０ 組成物
1 Raw material plant 2 Ashide 3 Ashide powder 4 Coarse particle component 5 Mineral component extract 6 Chitosan 10 Plant mineral 20 Composition
Claims (7)
前記原料植物由来のミネラル成分が、質量％で、ナトリウム（Ｎａ）０．４〜１．６％、カリウム（Ｋ）０．７〜２．８％、カルシウム（Ｃａ）５．７〜２３．０％、及びマグネシウム（Ｍｇ）１．４〜５．６％を含むことを特徴とする高尿酸血症を予防又は軽減する組成物。 Chitosan deacetylation degree of 80% or more, and mineral components derived from the raw material plants obtained from the ash of raw material plants, only including,
The mineral components derived from the raw material plants are sodium (Na) 0.4 to 1.6%, potassium (K) 0.7 to 2.8%, and calcium (Ca) 5.7 to 23.0 in mass%. %, And a composition for preventing or reducing hyperuric acidemia, which comprises 1.4 to 5.6% of magnesium (Mg).
脱アセチル化度が８０％以上であるキトサンと、
原料植物由来のミネラル成分と、を含み、
前記ミネラル成分は、原料植物を不活性雰囲気中で６５０℃以上に加熱することによって灰化し、得られた灰分を粉砕し、粉砕された灰分から可溶なミネラル成分を水で抽出し、生成したミネラル成分抽出液の水分を蒸発させ粉末化して製造することを特徴とする高尿酸血症を予防又は軽減する組成物の製造方法。 The method for producing a composition for preventing or reducing hyperuricemia according to any one of claims 1 to 3.
With chitosan, which has a degree of deacetylation of 80% or more,
Contains minerals derived from raw plants
The mineral component was produced by ashing the raw material plant by heating it to 650 ° C. or higher in an inert atmosphere, crushing the obtained ash, and extracting a soluble mineral component from the crushed ash with water. A method for producing a composition for preventing or reducing hyperuric acidemia, which is produced by evaporating the water content of a mineral component extract and pulverizing it.
The manufacturing process of the mineral component extract is characterized in that when the redox potential of the mineral component extract is less than -600 mV, an inert gas is further injected so that the redox potential becomes -600 mV or less. The method for producing a composition for preventing or reducing hyperuric acidemia according to claim 5.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019211858A JP6883350B2 (en) | 2019-11-22 | 2019-11-22 | Compositions for preventing or reducing hyperuricemia and methods for producing them |
| PCT/JP2020/043296 WO2021100837A1 (en) | 2019-11-22 | 2020-11-19 | Composition for preventing or reducing hyperuricemia, and method for producing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019211858A JP6883350B2 (en) | 2019-11-22 | 2019-11-22 | Compositions for preventing or reducing hyperuricemia and methods for producing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021080238A JP2021080238A (en) | 2021-05-27 |
| JP6883350B2 true JP6883350B2 (en) | 2021-06-09 |
Family
ID=75964229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019211858A Active JP6883350B2 (en) | 2019-11-22 | 2019-11-22 | Compositions for preventing or reducing hyperuricemia and methods for producing them |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP6883350B2 (en) |
| WO (1) | WO2021100837A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60197624A (en) * | 1984-03-21 | 1985-10-07 | Nippon Chemiphar Co Ltd | Urine-alkalizing food composition |
| JPH10130152A (en) * | 1996-10-28 | 1998-05-19 | Mtd Kk | Ultrafine crystal mineral liquid-containing chitin chitosan tablet |
| JP2004175680A (en) * | 2002-11-25 | 2004-06-24 | Marine Bio Kk | Mineral-containing composition having improving effect on biological balance |
| JP2006206474A (en) * | 2005-01-27 | 2006-08-10 | Rohto Pharmaceut Co Ltd | Functional food and medicine |
| JP4759337B2 (en) * | 2005-07-20 | 2011-08-31 | 栄基 中山 | Plant mineral extract and method for producing the same |
| JP2009120502A (en) * | 2007-11-13 | 2009-06-04 | Rohto Pharmaceut Co Ltd | Chitosan-containing composition |
| CN107088201A (en) * | 2017-04-24 | 2017-08-25 | 上海陶盛生物技术有限公司 | It is a kind of to be used to treat composition of gout and its production and use |
-
2019
- 2019-11-22 JP JP2019211858A patent/JP6883350B2/en active Active
-
2020
- 2020-11-19 WO PCT/JP2020/043296 patent/WO2021100837A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021080238A (en) | 2021-05-27 |
| WO2021100837A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bajaj et al. | Panchgavya: A precious gift to humankind | |
| WO2013073644A1 (en) | Combination health and functional food product comprising multiple minerals | |
| AU2016259438A1 (en) | Mitigation of animal and plant diseases using bioavailable minerals | |
| JP4100623B2 (en) | Composition of herbal extract with nicotine and dioxin detoxification | |
| CN108310287A (en) | Oral solution for the treatment of cancer and preparation method thereof | |
| US11717550B2 (en) | Method for preparing drinking water for livestock to create environment for revitalizing intestinal effective microorganisms using treatment of components via ion exchange of natural minerals | |
| JP6409151B1 (en) | Method for producing oral composition and oral composition | |
| JP6883350B2 (en) | Compositions for preventing or reducing hyperuricemia and methods for producing them | |
| JP2006087393A (en) | Health food and medicine | |
| RU2281957C1 (en) | Water-soluble sodium-, calcium-, iron-polygalactouronate stimulating hemopoiesis | |
| KR100793815B1 (en) | Method for removing toxic ingredients | |
| JPS6154389B2 (en) | ||
| JP2013159593A (en) | Method of detoxifying toxic substance and radioactive substance inside living body using lava powder and volcanic ash and method of improving polluted field | |
| WO2012017471A1 (en) | Natural medicinal compound | |
| Fatemi et al. | Clinical evaluation of desferrioxamine (DFO) for removal of thallium ions in rat | |
| EP2944314B1 (en) | Preparation for treating arthritis and arthrosis | |
| CN107296265A (en) | Accurate food synthetic balancing technique | |
| Tahiri et al. | Chronic oral administration of rhamnogalacturonan-II dimer, a pectic polysaccharide, failed to accelerate body lead detoxification after chronic lead exposure in rats | |
| KR20050080501A (en) | A making method of health assistance food for high blood pressure, fatness, diabetes patients. | |
| KR100486960B1 (en) | The health-supporting food being effective the hypertension and its preparation method | |
| WO2023112974A1 (en) | Hypertension-improving agent containing seaweed extract, and functional food, quasi-drug and drug containing hypertension-improving agent | |
| CN107281192A (en) | A kind of composition for mitigating, treating and prevent rheumatoid arthritis | |
| US20100189812A1 (en) | Agent for treating and/or preventing osteoporosis, comprising oceanic mineral components | |
| JP2003040783A (en) | Tungstic acid salt or molybdic acid salt and addition product of reishi spore useful as pharmaceutical product and health food | |
| CA2650368A1 (en) | An agent for treating and/or preventing osteoporosis, comprising oceanic mineral components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210224 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210406 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210427 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6883350 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |